Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development

• Published in: Scientific reports 2020-02, Vol.10 (1), p.2778-2778, Article 2778
• Main Authors: Nelson, Shannon R., Zhang, Chenxi, Roche, Sandra, O’Neill, Fiona, Swan, Niall, Luo, Yonglun, Larkin, AnneMarie, Crown, John, Walsh, Naomi
• Format: Article
• Language: English
• Subjects: 13; 13/106; 45/77; 45/91; 631/67/70; 692/4028/67/70; Adenocarcinoma; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Animals; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - pathology; Cell Differentiation - genetics; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic - genetics; Genome, Human - genetics; Genomics; Heterografts; High-throughput screening; Humanities and Social Sciences; Humans; Medical research; Mice; multidisciplinary; Organoids; Organoids - metabolism; Organoids - pathology; Pancreas - pathology; Pancreatic cancer; Primary Cell Culture - methods; Science; Science (multidisciplinary); Survival; Transcriptome - genetics; Tumor microenvironment; Tumor Microenvironment - genetics; Tumors; Xenografts
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-59368-7

With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) is the deadliest of all cancers. The rapid mortality makes PDAC difficult to research, and inspires a resolve to create reliable, tractable cellular models for preclinical cancer research. Organoids are increasingly used to model PDAC as they maintain the differentiation status, molecular and genomic signatures of the original tumour. In this paper, we present novel methodologies and experimental approaches to develop PDAC organoids from PDX tumours, and the simultaneous development of matched primary cell lines. Moreover, we also present a method of recapitulating primary cell line cultures to organoids (CLOs). We highlight the usefulness of CLOs as PDAC organoid models, as they maintain similar transcriptomic signatures as their matched patient-derived organoids and patient derived xenografts (PDX)s. These models provide a manageable, expandable in vitro resource for downstream applications such as high throughput screening, functional genomics, and tumour microenvironment studies.